CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Borgeat, A.
Right arrow Articles by Suter, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Borgeat, A.
Right arrow Articles by Suter, P. M.

Canadian Journal of Anesthesia, Vol 41, 1117-1119, Copyright © 1994 by Canadian Anesthesiologists' Society

ARTICLES

Adjuvant propofol enables better control of nausea and emesis secondary to chemotherapy for breast cancer

A Borgeat, O Wilder-Smith, M Forni and PM Suter
Department of Anesthesiology, University Hospital of Geneva, Switzerland.

We investigated the prophylactic antiemetic effect of added low-dose infusion of propofol in patients exhibiting nausea and vomiting refractory to dexamethasone and serotonin antagonist during non-cisplatin chemotherapy for breast cancer. In a prospective open longitudinal study, 117 patients who had more than five episodes of nausea and vomiting in their first chemotherapy cycle during the first 24 hr completed the study. They received in addition to the usual prophylactic antiemetic regimen a continuous intravenous infusion of 1 mg.kg-1.hr-1 propofol started four hours before chemotherapy and continued up to 24 hr for the two subsequent cycles. The number of vomiting/nausea episodes, level of sedation, patient activity, appetite and preference for future chemotherapy cycles were assessed. In the propofol supplemented cycles 90 and 80% of patients, during the 1st and 2nd propofol-assisted cycle respectively, were free of nausea and vomiting during the first 24 hr after chemotherapy. Patients were more frequently active and had more appetite during the propofol-assisted cycles. No propofol-associated side effects were observed. We conclude that the addition of a subhypnotic infusion of propofol enables better control of nausea and vomiting caused by non-cisplatin chemotherapy in the first 24 hr post-treatment.


This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
S. Tomioka, T. Kurio, K. Takaishi, and N. Nakajo
Propofol Is Effective in Chemotherapy-Induced Nausea and Vomiting: A Case Report with Quantitative Analysis
Anesth. Analg., September 1, 1999; 89(3): 798 - 798.
[Full Text] [PDF]

Home page
 NEJMHome page
R. A. Wiklund and S. H. Rosenbaum
Anesthesiology- First of Two Parts
N. Engl. J. Med., October 16, 1997; 337(16): 1132 - 1141.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the Canadian Anesthesiologists' Society.